Answers are grounded in this paper and cite their sources.
Behind the UK’s “landmark” pharma deal with the US lies a costly surrender, with higher drug prices, weaker safeguards, and vague promises of investment, write Els Torreele and Martin McKee
No takes yet. Share an insight, caveat, or question.
Torreele et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: